FDA Slaps Aurobindo Pharma with Form 483
Aurobindo Pharma stocks dropped 4.7% on BSE after the company said the FDA issued six large procedural observations for its Unit III, a formulation manufacturing facility located at Bachupally, Hyderabad.
The Food and Drug Administration conducted an inspection at the company’s Unit III, a formulation manufacturing facility located at Bachupally, Hyderabad, from April 10-18, 2017, according to an article in Business Standard.
The company said the observations were all regarding procedural improvements, and none of those were related to data integrity.
Read the full story